english.prescrire.org > Spotlight > 100 most recent

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

In the April issue of Prescrire International - Hydrochlorothiazide in hypertension: an acceptable first choice

FREE DOWNLOAD In countries where it is available, chlorthalidone is the first-choice thiazide diuretic. In France, where there is no available medicinal product containing chlorthalidone alone, the first-line thiazide diuretic is hydrochlorothiazide. How do these two drugs compare?
Full text available for free download.
1 April 2021

40 years: life goes on, so does Prescrire

 Editorial  The women and men who "make" and "are" Prescrire share strong values and work together to support a unique multidisciplinary movement for quality healthcare, launched 40 years ago.
1 April 2021

Drugs in 2020: a brief review

Just nine of the 109 new drugs, combinations, drug strengths, pharmaceutical forms or indictions analysed and rated in our French edition in 2020 constituted a notable therapeutic advance.
1 April 2021

Valproic acid: probable endocrine disruptor

Some of the adverse effects of valproic acid are linked to disruption of the human body's hormone systems. Children, especially those exposed in utero, and adolescents are particularly sensitive to effects of this type.
1 April 2021

Nasal decongestants withdrawn from the pan-European market

1 April 2021

• Safety signals: loss of sense of smell = danger

As the unending wave of medical information hits a fever pitch, it's more important then ever to remember to follow one's nose.
1 April 2021

Covid-19 vaccine Ad26.CoV2S (by Janssen): as with the other covid-19 vaccines, effective in the short term but unknowns remain

 NEWS UPDATE  Covid-19 vaccine Ad26.CoV2S, marketed by the pharmaceutical company Janssen (part of the Johnson & Johnson group), was authorised in the European Union on 11 March 2021. What are the main data available as of mid-March 2021 from clinical trials of covid-19 vaccine Ad26.CoV2S?
23 March 2021

The AstraZeneca covid-19 vaccine: British epidemiological data on the vaccination of older adults, and reassuring pharmacovigilance data

 NEWS UPDATE  ChAdOx1-S, the covid-19 vaccine marketed by the pharmaceutical company AstraZeneca, was authorised on the basis of comparative clinical trials conducted in 2020, from which it was not possible to evaluate the vaccine’s efficacy in older adults. As of March 2021, results available from two epidemiological studies conducted in the UK by public health agencies provide useful information about the vaccine’s efficacy during the first weeks following mass vaccination of older adults. At a time when 9.7 million first doses of this vaccine have been administered in the UK, no particular safety signals have been identified through British pharmacovigilance reporting.
15 March 2021

Messenger RNA covid-19 vaccines: Prescrire's in-depth analysis as of end February 2021

 COVID-19  The available clinical trial data have led the editors of independent French medical journal Prescrire to assign these vaccines the seldom-granted rating "A Real Advance".
02 March 2021

Covid-19: a recap of treatment options. From Prescrire's comprehensive year-end review

FEATURED REVIEW Very large amounts of data about covid-19 were published over the past year. As they became available, Prescrire sorted through to determine just which data were useful for the treatment and prevention of the disease.
Full review (3 pages) available for download by subscribers.
1 March 2021

1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90